Bi-weekly Cetuximab Combined With 5-fluorouracil/Leucovorin/Oxaliplatin (FOLFOX-6) in Metastatic Colorectal Cancer
Status:
Completed
Trial end date:
2016-09-01
Target enrollment:
Participant gender:
Summary
Cetuximab is normally given as a weekly schedule in the therapy of patients with metastatic
colorectal cancer.
In order to improve the convenience for the patients in first line-therapy this study will
evaluate the efficacy and safety of a bi-weekly combination of cetuximab with FOLFOX.